Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

Fig. 5

Evaluating the relationship between clinical efficacy and PD-L1 expression as determined by IHC staining in tumor biopsies. Subdivisions of PD-L1 expression by anti-PD-L1 antibody (DACO, 22C3) IHC staining to determine their correlation with objective response (a), OS (b) and PFS (c). PD-L1+ is defined as TPS ≥ 1% and CPS ≥ 1%, while PD-L1- is defined as TPS < 1% and CPS < 1%. The percentages of surviving patients are indicated at the specified time points. The numbers of patients at risk at the indicated time points are shown below the x-axis

Back to article page